OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 jul 2010 - 03:31
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces agreement with a US biotechnology company on its controlled release technology
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery company, announces today that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus’ controlled release technology.
Under the contract announced today, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.
Gerelateerde downloads
Datum laatste update: 01 september 2024